Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

BACKGROUND: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. METHODS: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349178/
https://www.ncbi.nlm.nih.gov/pubmed/22510747
http://dx.doi.org/10.1038/bjc.2012.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349178/
https://www.ncbi.nlm.nih.gov/pubmed/22510747
http://dx.doi.org/10.1038/bjc.2012.144

Ejemplares similares